373 related articles for article (PubMed ID: 31236798)
1. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.
Varlamov E; Hinojosa-Amaya JM; Stack M; Fleseriu M
Pituitary; 2019 Oct; 22(5):445-455. PubMed ID: 31236798
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Impact of [
Wannachalee T; Turcu AF; Bancos I; Habra MA; Avram AM; Chuang HH; Waguespack SG; Auchus RJ
Clin Endocrinol (Oxf); 2019 Aug; 91(2):288-294. PubMed ID: 31066920
[TBL] [Abstract][Full Text] [Related]
3. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.
Liu M; Cheng Y; Bai C; Zhao H; Jia R; Chen J; Zhu W; Huo L
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2002-2011. PubMed ID: 38337073
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
5.
El-Maouche D; Sadowski SM; Papadakis GZ; Guthrie L; Cottle-Delisle C; Merkel R; Millo C; Chen CC; Kebebew E; Collins MT
J Clin Endocrinol Metab; 2016 Oct; 101(10):3575-3581. PubMed ID: 27533306
[TBL] [Abstract][Full Text] [Related]
6. Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review.
Isidori AM; Sbardella E; Zatelli MC; Boschetti M; Vitale G; Colao A; Pivonello R;
J Clin Endocrinol Metab; 2015 Sep; 100(9):3231-44. PubMed ID: 26158607
[TBL] [Abstract][Full Text] [Related]
7. Value of the
Fastrez M; Artigas C; Sirtaine N; Wimana Z; Caillet M; Rozenberg S; Flamen P
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():69-74. PubMed ID: 28342392
[TBL] [Abstract][Full Text] [Related]
8. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of atypical
Gossili F; Almasi CE; Zacho HD
Hell J Nucl Med; 2023; 26(2):94-98. PubMed ID: 37527044
[TBL] [Abstract][Full Text] [Related]
10. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
11. Comparison of diagnostic efficacy of
Zhang B; He Q; Long Y; Zhang Y; Wang X; Chen Z; Liu J; Zhang X
Front Endocrinol (Lausanne); 2022; 13():962800. PubMed ID: 36213295
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic values of
Kumar R; Vankadari K; Mittal BR; Bansal D; Trehan A; Sahu JK; Sankhyan N
Eur Radiol; 2021 Jul; 31(7):4587-4594. PubMed ID: 33409780
[TBL] [Abstract][Full Text] [Related]
13. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
Lawal IO; Ololade KO; Lengana T; Reyneke F; Ankrah AO; Ebenhan T; Vorster M; Sathekge MM
Hell J Nucl Med; 2017; 20(2):128-133. PubMed ID: 28697189
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor-positive breast lesions on
Has Simsek D; Isik EG; Engin MN; Kuyumcu S; Mudun A; Sanli Y
Ann Nucl Med; 2021 Feb; 35(2):270-277. PubMed ID: 33400149
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.
Barrio M; Czernin J; Fanti S; Ambrosini V; Binse I; Du L; Eiber M; Herrmann K; Fendler WP
J Nucl Med; 2017 May; 58(5):756-761. PubMed ID: 28082438
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of
Ma H; Kan Y; Yang JG
Acta Radiol; 2021 Sep; 62(9):1217-1228. PubMed ID: 32985224
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
Kunikowska J; Lewington V; Krolicki L
Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
[TBL] [Abstract][Full Text] [Related]
19. Head-to-head comparison of
Liu Q; Zang J; Yang Y; Ling Q; Wu H; Wang P; Lu L; Zhu Z
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4386-4395. PubMed ID: 34146130
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]